Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


MHRA (UK) extends indication of Mavenclad (cladribine tablets) for relapsing forms of multiple sclerosis – Merck KGaA

Written by | 3 Apr 2024 | Neurology

Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by clinical or imaging features following approval by the MHRA, meaning more newly diagnosed patients could be eligible for treatment earlier in their disease course.

The approval in Great Britain makes the MHRA the first regulator in Europe to approve cladribine tablets for active relapsing MS. By allowing earlier use of cladribine tablets in the treatment pathway, this approval will expand access for the eligible patient population and will provide a new treatment option for these patients, improving patient outcomes and quality of life. he evidence and data show a favourable benefit to warrant use in this wider population.

Cladribine tablets first received regulatory approval for patients in Great Britain in 2017 for highly active relapsing MS as defined by clinical or imaging feature. In 2023, cladribine was included in the World Health Organisation’s Essential Medicines List.

Following the MHRA’s decision, Merck KGaA will be seeking reimbursement for use in the NHS. If successful, this would make cladribine tablets available to more patients in England, Wales, and Northern Ireland.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.